Human Prt1-like subunit protein (hPrt1) and human eIF4G-like protein (p97) genes

Abstract

The present invention relates to novel human Prt1 (hPrt1) and eIF4G-like (p97) proteins which are involved in eukaryotic transcription In particular, isolated nucleic acid molecules are provided encoding the human hPrt1 and p97 proteins. hprt1 and p97 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of hPrt1 and p97 activity. Also provided are therapeutic methods for treating disease states associated with the hPrt1 and p97 proteins.

What is claimed is:  
     
         1 . An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: 
 (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 873 in SEQ ID NO:2 or from about 1 to about 907 in SEQ ID NO:4;    (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about 2 to about 873 in SEQ ID NO:2 or from about 2 to about 907 in SEQ ID NO:4;    (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 147 to about 255 in SEQ ID NO:2;    (d) a nucleotide sequence encoding a polypeptide comprising amino acids from 185 to about 270 in SEQ ID NO:2;    (e) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97766 or 97767; and    (f) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), or (e).    
     
     
         2 . An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e), or (f) of  claim 1  wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.  
     
     
         3 . A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of  claim 1  into a vector.  
     
     
         4 . A recombinant vector produced by the method of  claim 3 .  
     
     
         5 . A method of making a recombinant host cell comprising introducing the recombinant vector of  claim 4  into a host cell.  
     
     
         6 . A recombinant host cell produced by the method of  claim 5 .  
     
     
         7 . A recombinant method for producing a hPrt1 or p97 polypeptide, comprising culturing the recombinant host cell of  claim 6  under conditions such that said polypeptide is expressed and recovering said polypeptide.  
     
     
         8 . An isolated hPrt1 or p97 polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of: 
 (a) amino acids from about 1 to about 873 in SEQ ID NO:2 or from about 1 to about 907 in SEQ ID NO:4;    (b) amino acids from about 2 to about 873 in SEQ ID NO:2 or from about 2 to about 907 in SEQ ID NO:4;    (c) amino acids from about 147 to about 255 in SEQ ID NO:2;    (d) amino acids from about 185 to about 270 in SEQ ID NO:2;    (e) the amino acid sequence of the hPrt1 or p97 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97766 or 97767; and    (f) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), or (e).    
     
     
         9 . An isolated antibody that binds specifically to a hPrt1 or p97 polypeptide of  claim 8 .  
     
     
         10 . A method of treating a disease state associated with apoptosis comprising introducing an effective amount of an hPrt1 and/or p97 protein into an individual to be treated in admixture with a pharmaceutically acceptable carrier.